Cerity Partners
TCRT icon

Cerity Partners’s Alaunos Therapeutics TCRT Stock Holding History

Cerity Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-364
Closed -$3.86K – 2350
2023
Q4 		$3.86K Buy
364
+4
+1% +$48 ﹤0.01% 1849
2023
Q3 		$7.12K Sell
360
-91
-20% -$3.92K ﹤0.01% 1384
2023
Q2 		$34.5K Buy
451
+178
+65% +$14.4K ﹤0.01% 1591
2023
Q1 		$25.8K Buy
+273
New +$26K ﹤0.01% 1818
2022
Q4 		– Sell
-91
Closed -$23K – 1524
2022
Q3 		$23K Hold
91
– – ﹤0.01% 1162
2022
Q2 		$17K Hold
91
– – ﹤0.01% 1168
2022
Q1 		$9K Buy
+91
New +$11.7K ﹤0.01% 933

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Cerity Partners's TCRT Position: Q1 2024 in Review

Cerity Partners sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 364 shares — an estimated $3.86K sold.

Cerity Partners first reported a position in TCRT in Q1 2022 and held it in 7 quarters. The position peaked at $34.5K in Q2 2023. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Cerity Partners reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cerity Partners sold 364 Alaunos Therapeutics shares in Q1 2024, an estimated $3.86K.
  • Cerity Partners first reported a position in Alaunos Therapeutics in Q1 2022 and held it in 7 quarters.
  • Cerity Partners's Alaunos Therapeutics position peaked at $34.5K in Q2 2023.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Cerity Partners's 13F filing for Q1 2024, filed 14 May 2024.